



SEPTEMBER 29<sup>th</sup>, 2022  
1:00 pm CEST

## THE FUTURE OF BIOBETTERS

Biosimilars are increasingly used to treat patients with IMiDs. Biobetters have changed the way oncology patients are treated. Biobetters may be associated with improvements in clinical outcomes and drug pharmacology. The first anti-TNF biobetter was recently approved for IBD. During this exciting webinar, the experience from non-IBD conditions will be reviewed, regulatory pathways will be discussed, and biobetters that are in the pipeline will be presented. This will be accompanied by a fruitful discussion among the Faculty that will interact with the audience during the Q&A session!

*Chairs: Silvio Danese, Italy  
Laurent Peyrin-Biroulet, France*

### FACULTY

**Silvio Danese**  
Professor of Gastroenterology,  
Head of Gastroenterology and Endoscopy  
San Raffaele Hospital, Milan, Italy

**Laurent Peyrin-Biroulet**  
Full Professor of Medicine IBD Unit  
Department of Gastroenterology Nancy  
University Hospital, France

**Fernando Magro**  
Professor Pharmacology and Therapeutics  
University of Porto - Porto, Portugal  
Consultant gastroenterologist, Centro Hospitalar de São João  
and Director of Clinical Pharmacology  
Founded the Portuguese IBD Group (GEDII)

**Walter Reinisch**  
Department of Medicine IV,  
Medical University Vienna - Austria

**Stefan Schreiber**  
Director, Department for Internal Medicine I and  
Director, Institute for Clinical Molecular Biology,  
Medical Faculty, Christian Albrechts-University,  
Kiel University Hospital Schleswig-Holstein, Germany

### Intro

Silvio Danese, *Italy*  
Laurent Peyrin-Biroulet, *France*

### Lessons from non IBD conditions 15'

Fernando Magro, *Portugal*

### Regulatory approval 15'

Walter Reinisch, *Austria*

### New formulations

### - example for a bio better? 15'

Stefan Schreiber, *Germany*

### Q&A 10'

[CLICK HERE  
TO REGISTER](#)

Sponsored by



ORGANIZATION OFFICE  
Materia Prima srl  
segreteria@materia1a.it | materia1a.it  
ibdscope@ibdscope.com